[1]檀占海,陈建荣,张吉发,等.胰腺癌组织中METTL14 和GFPT1 的水平表达与临床预后价值研究[J].现代检验医学杂志,2023,38(05):99-104.[doi:10.3969/j.issn.1671-7414.2023.05.019]
　TAN Zhanhai,CHEN Jianrong,ZHANG Jifa,et al.Expression of METTL14 and GFPT1 in Pancreatic Cancer and Their Clinical Prognostic Value[J].Journal of Modern Laboratory Medicine,2023,38(05):99-104.[doi:10.3969/j.issn.1671-7414.2023.05.019]
点击复制

胰腺癌组织中METTL14 和GFPT1 的水平表达与临床预后价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年05期
页码:
99-104
栏目:
论著
出版日期:
2023-09-15

文章信息/Info

Title:
Expression of METTL14 and GFPT1 in Pancreatic Cancer and Their Clinical Prognostic Value
文章编号:
1671-7414（2023）05-099-06
作者:
檀占海; 陈建荣; 张吉发; 周联明; 单远洲
(上海交通大学附属第六人民医院南院普外科，上海 201499)
Author(s):
TAN Zhanhai;  CHEN Jianrong;  ZHANG Jifa;  ZHOU Lianming;  SHAN Yuanzhou
（Department of General Surgery, South Hospital of the Sixth People’s Hospital Affiliated to Shanghai Jiaotong University, Shanghai 201499, China）
关键词:
胰腺癌; 甲基转移酶14; 谷氨酰胺- 果糖-6- 磷酸转氨酶
分类号:
R735.9；R730.43
DOI:
10.3969/j.issn.1671-7414.2023.05.019
文献标志码:
A
摘要:
目的 研究胰腺癌组织中甲基转移酶14（methyltransferase 14，METTL14）及谷氨酰胺- 果糖-6- 磷酸转氨酶1（glutamine-fructose-6-phosphate transaminase 1，GFPT1）的表达及其临床意义。方法 选取2017 年4 月～ 2019年4 月上海交通大学附属第六人民医院诊治的86 例胰腺癌患者为研究对象。利用实时定量PCR 检测癌和癌旁组织中METTL14 和GFPT1 mRNA 水平表达。利用免疫组织化学检测癌和癌旁组织中METTL14 和GFPT1 蛋白表达。相关性分析采用Pearson 相关分析及Spearman 秩相关分析。比较不同胰腺癌患者METTL14 和GFPT1 蛋白表达与临床病理参数的关系。Kaplan-Meier 生存分析胰腺癌组织中METTL14 和GFPT1 蛋白表达与患者生存预后的关系。单因素及多因素COX 模型评价影响胰腺癌预后的因素。结果 胰腺癌组织中METTL14 mRNA（5.442±0.437 ），GFPT1 mRNA（6.521±0.516）表达高于癌旁组织（0.992±0.203，0.895±0.212），差异具有统计学意义（t=85.644，93.525，均P ＜ 0.05）。胰腺癌组织中METTL14（73.26%），GFPT1（69.77%）蛋白表达阳性率高于癌旁组织（8.14%，9.30%），差异具有统计学意义（χ2=75.545，65.765，均P ＜ 0.05）。胰腺癌组织中METTL14 mRNA 与GFPT1 mRNA 的表达呈明显正相关性（r=0.569，P ＜ 0.05）；METTL14 蛋白与GFPT1 蛋白表达呈明显正相关性（r=0.664，P ＜ 0.05）。低分化程度（92.31%，88.46%）、AJCC 分期Ⅱ～Ⅲ期（89.13%，86.96%）及有淋巴结转移（95.12%，92.68%）胰腺癌组织中METTL14，GFPT1 蛋白表达阳性率分别高于高中分化程度（65.00%，61.67%）、AJCC 分期Ⅰ期（55.00%，50.00%）及无淋巴结转移（53.33%，48.89%），差异具有统计学意义（χ2=6.174 ～ 19.507，均P<0.05）。METTL14 阳性表达组和GFPT1阳性表达组患者三年累积生存率分别低于METTL14 阴性表达组，GFPT1 阴性表达组（χ2=15.232，18.054，均P ＜ 0.05）。肿瘤AJCC 分期Ⅱ～Ⅲ期（OR=2.552, 95%CI=1.420 ～ 4.455）、伴淋巴结转移（OR=1.754, 95%CI=1.125 ～ 2.534）、METTL14 阳性（OR=2.797, 95%CI=1.233 ～ 5.876）、GFPT1 阳性（OR=1.635, 95%CI=1.030 ～ 2.506）是影响胰腺癌预后的独立危险因素。结论 胰腺癌组织中METTL14，GFPT1 表达升高，两者与肿瘤AJCC 分期、肿瘤分化程度和淋巴结转移有关，可用于评价胰腺癌患者生存预后。
Abstract:
Objective To study the expression and clinical significance of methyltransferase 14 (METTL14) and glutamine fructose-6-phosphate aminotransferase 1 (GFPT1) in pancreatic cancer. Methods 86 patients with pancreatic cancer diagnosed and treated in South Hospital of the Sixth People’s Hospital Affiliated to Shanghai Jiaotong University from April 2017 to April 2019 were selected as the study subjects. METTL14 and GFPT1 mRNA expression in cancer and adjacent tissues were detected by real-time quantitative PCR. Immunohistochemistry was used to detect METTL14 and GFPT1 protein expression in cancer and adjacent tissues. Pearson correlation analysis and Spearman rank correlation analysis were used for correlation analysis. The relationship between the expression of METTL14, GFPT1 and clinicopathological parameters in different pancreatic cancer patients was compared. Kaplan Meier survival was used to analyze the relationship between the expression of METTL14 and GFPT1 in pancreatic cancer and the survival prognosis of patients. Univariate and multivariate COX models were used to evaluate the prognostic factors of pancreatic cancer. Results The expression of METTL14 mRNA (5.442 ± 0.437 ) and GFPT1 mRNA (6.521 ± 0.516) in pancreatic cancer tissue was significantly higher than that in paracancerous tissue（0.992±0.203，0.895±0.212），and the differences were statistically significant(t=85.644，93.525，all P<0.05). The positive rate of METTL14 (73.26%) and GFPT1 (69.77%) protein expression in pancreatic cancer tissues was higher than that in paracancerous tissues（8.14%，9.30%）, and the differences were statistically significant（χ2=75.545，65.765，all P<0.05). The expression of METTL14 and GFPT1 mRNA in pancreatic cancer tissue was positively correlated (r=0.569, P<0.05). There was a significant positive correlation between METTL14 and GFPT1 protein expression (r=0.664, P=0.000). The positive rate of METTL14 and GFPT1 protein expression in pancreatic cancer tissues with poor differentiation（92.31%，86.96%）, AJCC stage Ⅱ ~ Ⅲ （89.13%，86.96%）and lymph node metastasis （95.12%，92.68%）was higher than that in high differentiation （65.00%，61.67%）, AJCC stage Ⅰ（55.00%，50.00%） and no lymph node metastasis（53.33%，48.89%）, respectively, with statistical significance（χ2=6.174 ～ 19.507，all P<0.05). The 3-year cumulative survival rates of patients in the METTL14 positive expression group and GFPT1 positive expression group were lower than those in the METTL14 negative expression group and GFPT1 negative expression group, respectively（χ2=15.232, 18.054, all P<0.05). Tumor AJCC stage Ⅱ~Ⅲ (OR=2.552, 95% CI=1.420 ～ 4.455), with lymph node metastasis (OR=1.754, 95% CI=1.125 ～ 2.534), METTL14 positive expression (OR=2.797, 95%CI=1.233 ～ 5.876), GFPT1 positive expression (OR=1.635, 95%CI=1.030 ～ 2.506) were independent risk factors affecting the prognosis of pancreatic cancer. Conclusion The increased expression of METTL14 and GFPT1 in pancreatic cancer were related to tumor AJCC stage, tumor differentiation and lymphocyte metastasis, which can be used to evaluate the survival prognosis of pancreatic cancer patients.

参考文献/References:

[1] KLEIN A P. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors[J].Nature Reviews. Gastroenterology & Hepatology, 2021, 18(7): 493-502.
[2] CAI Jie, CHEN Hongda, LU Ming, et al. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis[J]. Cancer Letters, 2021, 520: 1-11.
[3] SPRINGFELD C, J?GER D, B?CHLER M W, et al. Chemotherapy for pancreatic cancer[J]. Presse Med, 2019, 48(3 Pt 2): e159-e174.
[4] YANG Xiao, ZHANG Sen, HE Changyu, et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST[J]. Molecular Cancer, 2020, 19(1): 46.
[5] FAN Huining, CHEN Zhaoyu, CHEN Xiaoyu, et al. METTL14-mediated m6A modification of circORC5 suppresses gastric cancer progression by regulating miR-30c-2-3p/AKT1S1 axis[J]. Molecular Cancer, 2022, 21(1): 51.
[6] ZHANG Chunyan, LIAN Hongkai, XIE Linsen, et al. LncRNA ELFN1-AS1 promotes esophageal cancer progression by up-regulating GFPT1 via sponging miR-183-3p[J]. Biological Chemistry, 2020, 401(9): 1053-1061.
[7] LI Dailing, GUAN Mingmei, CAO Xiaofei, et al. GFPT1 promotes the proliferation of cervical cancer via regulating the ubiquitination and degradation of PTEN[J]. Carcinogenesis, 2022, 43(10):969-979.
[8] 韦莉, 缪淑贤, 王敏, 等. 胰腺癌患者血清尿酸、肌酐水平检测及尿酸/ 肌酐比值的临床意义[J]. 现代检验医学杂志, 2019, 34(4): 99-102. WEI Li, MIAO Shuxian, WANG Min, et al. Clinical significance of serum uric acid, creatinine and uric acid/creatinine ratio in pancreatic ductal adenocarcinoma[J].Journal of Modern Laboratory Medicine, 2019, 34(4): 99-102.
[9] 袁蒙, 阿卜杜海拜尔·萨杜拉, 任思谦, 等. 胰腺癌免疫微环境特点与相关免疫治疗策略[J]. 中华医学杂志, 2021, 101(12): 831-835. YUAN Meng, ABUDUHAIBAIER Sadulla, REN Siqian, et al. Characteristics of pancreatic ductal adenocarcinoma immune microenvironment and related immunotherapy strategies[J]. National Medical Journal of China, 2021, 101(12): 831-835.
[10] TANG Yujiao, CHEN Kunqi, SONG Bowen, et al. M6A-Atlas: a comprehensive knowledgebase for unraveling the N6-methyladenosine (m6A) epitranscriptome[J]. Nucleic Acids Research, 2021, 49(D1): D134-D143.
[11] YANG Zizhao, YANG S, CUI Yanhong, et al. METTL14 facilitates global genome repair and suppresses skin tumorigenesis[J]. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118(35):e2025948118.
[12] CHEN Xiaoxiang, XU Mu, XU Xueni, et al. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer[J]. Molecular Cancer, 2020, 19(1): 106.
[13] CHEN Shi, YANG Can, WANG Zuwei, et al. CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer[J]. Journal of Hematology & Oncology, 2021, 14(1): 60.
[14] WANG Min, LIU Jun, ZHAO Yan, et al. Upregulation of METTL14 mediates the elevation of PERP mRNA N 6 adenosine methylation promoting the growth and metastasis of pancreatic cancer[J]. Molecular Cancer, 2020, 19(1): 130.
[15] 蒯榕, 徐莹, 褚以忞, 等.m6A RNA 甲基转移酶METTL3 对肠癌细胞上皮间质转化及侵袭能力的影响[J]. 现代生物医学进展, 2021, 21(21): 4019-4023,4074. KUAI Rong, XU Ying, CHU Yimin, et al. The role of METTL3 in the EMT and invasion ability in colorectal cancer cells[J]. Progress in Modern Biomedicine, 2021, 21(21): 4019-4023, 4074.
[16] GONG Shulei, WANG Shiyang, SHAO Mingrui. Mechanism of METTL14-mediated m6A modification in non-small cell lung cancer cell resistance to cisplatin[J]. Journal of Molecular Medicine (Berlin, Germany), 2022, 100(12):1771-1785.
[17] ZHANG Chunyan, LIAN Hongkai, XIE Linsen, et al. LncRNA ELFN1-AS1 promotes esophageal cancer progression by up-regulating GFPT1 via sponging miR-183-3p[J]. Biological Chemistry, 2020, 401(9): 1053-1061.
[18] JIA Chunzeng, LI Hengchao, FU Deliang, et al. GFAT1/HBP/O-GlcNAcylation axis regulates β-catenin activity to promote pancreatic cancer aggressiveness[J].BioMed Research International, 2020, 2020:1921609. .
[19] ZHANG Xiao, YU Keke, MA Lifang, et al. Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma[J]. Theranostics, 2021, 11(12):5650-5674.
[20] HUANG Huang, WANG Yuhan, HUANG Tianmiao, et al. FOXA2 inhibits doxorubicin-induced apoptosis via transcriptionally activating HBP rate-limiting enzyme GFPT1 in HCC cells[J]. Journal of Physiology and Biochemistry, 2021, 77(4): 625-638.
[21] SHI Qingzhu, SHEN Qicong, LIU Yanfang, et al. Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance[J]. Cancer Cell, 2022, 40(10): 1207-1222.e10.

相似文献/References:

[1]党珊a,周健a,杨帆b,等.胰腺癌组织中缺氧诱导因子-2α的表达及临床意义[J].现代检验医学杂志,2015,30(06):32.[doi:10.3969/j.issn.1671-7414.2015.06.009]
　DANG Shana,ZHOU Jiana,YANG Fanb,et al.Expression of Hypoxia Inducible Factor 2α in Pancreatic Carcinoma and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2015,30(05):32.[doi:10.3969/j.issn.1671-7414.2015.06.009]
[2]韦 莉,缪淑贤,王 敏,等.胰腺癌患者血清尿酸、肌酐水平检测及尿酸/肌酐比值的临床意义[J].现代检验医学杂志,2019,34(04):99.[doi:10.3969/j.issn.1671-7414.2019.04.024]
　WEI Li,MIAO Shu-xian,WANG Min,et al.Clinical Significance of Serum Uric Acid,Creatinine and Uric Acid/Creatinine Ratio in Pancreatic Ductal Adenocarcinoma[J].Journal of Modern Laboratory Medicine,2019,34(05):99.[doi:10.3969/j.issn.1671-7414.2019.04.024]
[3]邢瑞青,彭道荣,刘　杨.血清CA199，KL-6和PIVKA-Ⅱ水平联合检测在胰腺癌诊断中的应用价值分析[J].现代检验医学杂志,2021,36(05):100.[doi:10.3969/j.issn.1671-7414.2021.05.022]
　XING Rui-qing,PENG Dao-rong,LIU Yang.Application Value of Combined Detection of Serum CA199,KL-6 andPIVKA -Ⅱ Levels in the Diagnosis of Patients with Pancreatic Cancer[J].Journal of Modern Laboratory Medicine,2021,36(05):100.[doi:10.3969/j.issn.1671-7414.2021.05.022]
[4]王东琴,霍浩然,秦瑞峰,等.胰腺癌患者血清 lncRNA-SNHG11的表达水平及其临床意义[J].现代检验医学杂志,2022,37(01):125.[doi:10.3969/j.issn.1671-7414.2022.01.025]
　WANG Dong-qin,HUO Hao-ran,QIN Rui-feng,et al.Expression Level of Serum lncRNA-SNHG11 in Patients with Pancreatic Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2022,37(05):125.[doi:10.3969/j.issn.1671-7414.2022.01.025]
[5]王军堂a,齐普良a,张金刚a,等.hsa_circ_0006950 调控miR-124-3p/EZH2 轴促进胰腺癌细胞增殖与迁移的机制研究[J].现代检验医学杂志,2022,37(05):93.[doi:10.3969/j.issn.1671-7414.2022.05.019]
　WANG Jun-tanga,QI Pu-lianga,ZHANG Jin-ganga,et al.Mechanism of hsa_circ_0006950 Regulating miR-124-3p /EZH2 Axis to Promote the Proliferation and Migration of Pancreatic Cancer Cells[J].Journal of Modern Laboratory Medicine,2022,37(05):93.[doi:10.3969/j.issn.1671-7414.2022.05.019]
[6]张莉娜,张霁雯,罗 酩,等.胰腺癌组织CTTN 和miR-545-3p 表达水平及其与临床病理和预后的相关性研究[J].现代检验医学杂志,2022,37(06):99.[doi:10.3969/j.issn.1671-7414.2022.06.018]
　ZHANG Li-na,ZHANG Ji-wen,LUO Ming,et al.Expression Levels of CTTN and miR-545-3p in Pancreatic Cancer Tissues and Their Correlation with Clinicopathology and Prognosis[J].Journal of Modern Laboratory Medicine,2022,37(05):99.[doi:10.3969/j.issn.1671-7414.2022.06.018]
[7]张立洁a,彭 泉b.基于GEO 数据库筛选慢性胰腺炎恶变过程中关键miRNA 和ceRNA 网络构建[J].现代检验医学杂志,2023,38(02):18.[doi:10.3969/j.issn.1671-7414.2023.02.004 ]
　ZHANG Li-jiea,PENG Quanb.Screening of Key miRNAs and Construction of Competing Endogenous RNA Network Involved in the Progression from Chronic Pancreatitis to Pancreatic Cancer Based on GEO Database[J].Journal of Modern Laboratory Medicine,2023,38(05):18.[doi:10.3969/j.issn.1671-7414.2023.02.004 ]
[8]夏菊芳,刘 洪.胰腺癌组织中KYNU mRNA 的表达及其与免疫浸润和预后的相关性研究[J].现代检验医学杂志,2024,39(02):57.[doi:10.3969/j.issn.1671-7414.2024.02.011]
　XIA Jufang,LIU Hong.Expression of KYNU mRNA in Pancreatic Cancer Tissue and Its Correlation with Immune Infiltration and Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(05):57.[doi:10.3969/j.issn.1671-7414.2024.02.011]

备注/Memo

备注/Memo:
基金项目：上海市科研计划项目（N0:1644901000）：胰腺癌组织中METTL14，GFPT1 的表达及临床预后的关系研究。
作者简介：檀占海（1979-），男，硕士，副主任医师，研究方向：肝胆胰疾病，E-mail：tanzhanhai2015@163.com。
通讯作者：单远洲（1964-），男，本科，主任医师，研究方向：肝胆胰、乳腺疾病，E-mail：gzy653@126.com。
更新日期/Last Update: 2023-09-15